在2026年AACR会议上,Antengene为针对固体瘤的三种实验性癌症药物提出了有希望的临床前结果. Antengene presents promising preclinical results for three experimental cancer drugs targeting solid tumors at the 2026 AACR meeting.

在2026年AACR年度会议上,Antengene将介绍三种实验性癌症治疗的临床前数据. Antengene will present preclinical data on three experimental cancer therapies at the 2026 AACR Annual Meeting. 针对B7-H3和PD-L1的双特异抗体药物联ATG-125通过有效地提供细胞毒性负载,在固体瘤模型中显示出强烈的抗瘤活性. ATG-125, a bispecific antibody-drug conjugate targeting B7-H3 and PD-L1, showed strong antitumor activity in solid tumor models by effectively delivering a cytotoxic payload. 在卵巢和脏癌模型中,ATG-106是一种CDH6 x CD3T细胞激活剂,在最小的细胞因子释放下显示出强大的瘤特异性T细胞活性. ATG-106, a CDH6 x CD3 T-cell engager, demonstrated potent tumor-specific T-cell activation with minimal cytokine release in ovarian and kidney cancer models. 针对ALPPL2/ ALPG的ATG-112在妇科和消化系统癌症中表现出选择性瘤向和强烈的抗瘤反应. ATG-112, targeting ALPPL2/ALPG, exhibited selective tumor targeting and strong antitumor responses in gynecological and digestive cancers. 所有候选药物旨在提高治疗固体瘤的疗效和安全性. All candidates are designed to enhance efficacy and safety in treating solid tumors.